Article Sidebar

PDF
Date Published: 23/06/2022
Abstract Views: 348
Views PDF: 514
DOI: https://doi.org/10.51298/vmj.v515i2.2760
Issue
Vol. 515 No. 2 (2022)
Section
Các bài báo
How to Cite
Kim Thư, N. ., & Viết Nghĩa, L. . (2022). EVALUATION OF TREATMENT RESULTS IN BURKHOLDERIA PSEUDOMALLEI INFECTED PATIENTS AT THE NATIONAL HOSPITAL FOR TROPICAL DISEASES FROM 2016-2021. Vietnam Medical Journal, 515(2). https://doi.org/10.51298/vmj.v515i2.2760

EVALUATION OF TREATMENT RESULTS IN BURKHOLDERIA PSEUDOMALLEI INFECTED PATIENTS AT THE NATIONAL HOSPITAL FOR TROPICAL DISEASES FROM 2016-2021

Nguyễn Kim Thư1,2,, Lê Viết Nghĩa2
1 National Hospital for Tropical Diseases
2 Hanoi Medical University

Main Article Content

Abstract

Objectives: evaluation of a treatment outcome of patients infected with Burkholderia pseudomallei at the National Hospital for Tropical Diseases. Methods: cross-sectional study was conducted on 79 patients with confirmed of Burkholderia pseudomallei infection, between 2016 and 2021, at National Hospital of Tropical Diseases. Results and conclusions: Antibiotic susceptibility rate of 75 Burkholderia pseudomallei isolates: imipenem 93,2%; meropenem 96,3%; ceftazidim 93,3%; Amo + A.clavulanic 88,4%; TMP-SMX 82,2%; doxycyclin 100%; Tetracyclin 76,2%. Antibiotic resistance rate of 75 Burkholderia pseudomallei isolates: imipenem 2,7%; meropenem 3,7%; ceftazidim 1,3%; Amo + A.clavulanic 9,3%; TMP-SMX 16,4%; tetracyclin 14,3%. TMP-SMX did not reduce mortality rate and fever time when combined with intravenous antibiotics. The overall mortality rate was 11.4%. The mean hospital stay period was 26.72 ± 16.20 days. The fever time after treatment was mainly less than 7 days, accounting for 53.4%.

Article Details

Keywords

Melioidosis, Burkholderia pseudomallei

References

1. Wiersinga WJ, Virk HS, Torres AG, et al. Melioidosis. Nat Rev Dis Primers. 2018;4:17107. doi:10.1038/nrdp.2017.107
2. Nguyễn Quang Huy. Nghiên cứu đặc điểm lâm sàng, cận lâm sàng và bước đầu đánh giá kết quả điều trị bệnh nhân nhiễm khuẩn huyết do Burkholderia pseudomallei. Luận văn thạc sĩ y học. Published online 2017.
3. Nhung PH, Van VH, Anh NQ, Phuong DM. Antimicrobial susceptibility of Burkholderia pseudomallei isolates in Northern Vietnam. J Glob Antimicrob Resist. 2019;18:34-36. doi:10.1016/ j.jgar.2019.01.024
4. Saiprom N, Amornchai P, Wuthiekanun V, et al. Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei from Thailand. Int J Antimicrob Agents. 2015;45(5):557-559. doi:10.1016/j.ijantimicag.2015.01.006
5. Wuthiekanun V, Cheng AC, Chierakul W, et al. Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. J Antimicrob Chemother. 2005;55(6):1029-1031. doi:10.1093/jac/dki151
6. Chierakul W, Anunnatsiri S, Short JM, et al. Two Randomized Controlled Trials of Ceftazidime Alone versus Ceftazidime in Combination with Trimethoprim-Sulfamethoxazole for the Treatment of Severe Melioidosis. Clinical Infectious Diseases. 2005;41(8):1105-1113. doi:10.1086/444456
7. Churuangsuk C, Chusri S, Hortiwakul T, Charernmak B, Silpapojakul K. Characteristics, clinical outcomes and factors influencing mortality of patients with melioidosis in southern Thailand: A 10-year retrospective study. Asian Pac J Trop Med. 2016; 9(3):256-260. doi:10.1016/ j.apjtm.2016.01.034
8. Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis. 2010;4(11):e900. doi:10.1371/ journal.pntd.0000900